Trials of a vaccine being developed in the UK have shown results of up to 90% efficacy under a lower dosage regime.

Oxford University and pharmaceutical giant AstraZeneca said on 23 November that one dosing regime, in which participants were given a half dose, followed by a full dosage at least one month apart, showed an efficacy rate of 90%.